



# Evaluate Japan Drug Forecasts to 2022

Conduct external benchmarking & market analysis with the first consensus forecasts for Japan

Our industry-leading consensus forecasts, combined with historical sales and sales by indication for the Japanese market will help you make business critical decisions faster.

Evaluate Japan Drug Forecasts cover over 1,000 marketed and R&D products which make up over 80% of the total Japanese market value in 2016.

## Product Valuation

Create product and company portfolio valuations for Japan market with standardised consensus forecasts to 2022

## Competitive Analysis

Benchmark product performance and map uptake trends and key drivers for Japan market

## Market Sizing

Model the future dynamics of the Japanese market to 2022 and compare worldwide, USA and EU consensus forecasts


## Sales by Indication

Model product sales at indication level and identify the key growth drivers

## Horizon Scanning

Map pipeline assets likely to launch by 2022 and measure impact to understand future asset value

**1,000+ Products covered – >80% of total Japan market in 2016**



## Sales by indication

Available for the top 25+ companies, including Takeda, Astellas Pharma, Daiichi Sankyo, Roche and more.





Evaluate is the trusted provider of commercial intelligence including product sales and consensus forecasts to 2022 for commercial teams and their advisors within the global life science industry. We help our clients make high value decisions through superior quality, timely, must-have data and insights, combined with personalised, expert client support.

**EvaluatePharma**<sup>®</sup> delivers exclusive consensus sales forecasts and trusted commercial insight into biotech and pharmaceutical performance.

 [@EvaluatePharma](#)

**EvaluateMedTech**<sup>®</sup> sets a new standard in commercial analysis and consensus forecasts of the global medical device and diagnostic industry.

 [@EvaluateMedTech](#)

**EvaluateClinical Trials**<sup>®</sup> delivers unique clinical trial intelligence expertly curated to efficiently analyse the global clinical trial landscape.

 [@EPClinicalTrial](#)

**EP Vantage** an award winning editorial team, provides daily commentary and analysis with fresh perspectives and insight into current and future industry trends.

 [@EPVantage](#)

**Evaluate Custom Services** provides customised solutions to help you access, analyse and manage the information you need to support effective decision-making.

The Evaluate services enable the life science community to make sound business decisions about value and opportunity.

[www.evaluate.com](http://www.evaluate.com)

---

**Evaluate Headquarters**

Evaluate Ltd.  
11-29 Fashion Street  
London E1 6PX  
United Kingdom  
T +44 (0)20 7377 0800  
F +44 (0)20 7539 1801

**Evaluate Americas**

EvaluatePharma USA Inc.  
60 State Street, Suite 1910  
Boston, MA 02109  
USA  
T +1 617 573 9450  
F +1 617 573 9542

**Evaluate Asia Pacific**

Evaluate Japan KK  
Akasaka Garden City 4F  
4-15-1 Akasaka, Minato-ku  
Tokyo 107-0052  
Japan  
T +81 (0)80 1164 4754